查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2092094

氣喘治療市場－全球市場預測（2026-2032年）

Asthma Therapeutics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，氣喘治療市場將成長至 420.7 億美元，複合年成長率為 5.84%。

主要市場統計數據
基準年 2025 282.6億美元
預計年份：2026年 298.1億美元
預測年份 2032 420.7億美元
複合年成長率 (%) 5.84%

隨著臨床醫生、保險公司和公共衛生系統應對慢性發炎性氣道疾病持續對全球兒童和成人的負擔，氣喘治療正朝著更精準化的方向發展。全球醫學檢驗表明，氣喘是一種主要的非傳染性呼吸系統疾病，其特徵是喘息、呼吸困難、胸悶、咳嗽、急診就診、生產力下降，以及若症狀得不到控制則可能導致的死亡。治療方案包括吸入性糖皮質激素、長效支氣管擴張劑、白三烯通路調節劑、短效緩解藥物、複方吸入劑、用於急性發作的口服類固醇，以及針對重症氣喘表現型的生物目標製劑。目前的臨床指引越來越強調，不僅要緩解症狀，還要重視抗發炎緩解治療策略、最佳化用藥依從性、指導正確的吸入技巧、個人化和階梯式治療，以及降低急性發作風險。影響氣喘治療的 SEO 相關行業主題包括：重症氣喘的生物製藥、嗜酸性粒細胞氣喘的治療、過敏性氣喘的管理、吸入皮質類固醇的依從性、智慧吸入器、數位呼吸護理、兒童氣喘治療以及基於價值的呼吸系統疾病管理。

氣喘治療前景的變革性變化

氣喘治療格局正受到臨床、監管、技術和環境變化的影響而重塑。其中一個核心轉變是從統一的支氣管擴張療法轉向基於表現型和生物標記的治療。這包括利用血液嗜酸性粒細胞計數、免疫球蛋白E (IgE) 水平、呼出氣一氧化氮分數 (frNO)、急性發作史、合併症和治療反應等因素來指導重症氣喘的治療選擇。過度使用短效BETA2受體激動劑會增加急性發作的風險，指引也越來越建議減少對其的依賴。同時，包含吸入性糖皮質激素的方案仍是減輕氣道發炎的基礎治療方案。另一個顯著的變化是針對II型發炎路徑的生物製藥的擴展，這為儘管最佳化了吸入療法但症狀仍然持續存在的重度氣喘控制不佳患者提供了治療支持。同時，數位吸入器、連網霧化系統、遠端監測以及支援用藥依從性的電子工具正在改變臨床醫生識別吸入技術缺陷、用藥依從性差和病情控制惡化的方式。環境和職業因素、空氣污染、接觸氣候相關過敏原、病毒性呼吸道感染疾病、接觸菸草煙霧以及室內空氣品質仍然影響疾病控制，氣喘治療與預防、診斷和公共衛生干預措施的關聯也日益緊密。

人工智慧對氣喘治療的累積影響

人工智慧 (AI) 透過改善診斷支援、風險分層、監測吸入器依從性、臨床試驗設計以及產生真實世界證據，對氣喘治療整體產生累積影響。 AI 演算法可以分析電子健康記錄、藥房處方續開模式、處方箋測試結果、症狀日記、保險理賠數據、穿戴式裝置訊號以及環境暴露訊息，從而識別出氣喘急性發作高風險或控制不佳的患者。在臨床開發中，機器學習正在輔助生物標記發現、重症氣喘試驗中的患者選擇、方案最佳化以及分析不同表現型（例如嗜酸性粒細胞氣喘、過敏性氣喘、非 2 型氣喘、運動誘發性氣喘和兒童氣喘）治療反應的異質性。在醫療服務中，AI 驅動的數位呼吸平台有助於檢測安寧療護藥物的過度使用、維持藥物的漏服、異常的峰值流速趨勢和季節性觸發模式，從而實現更早的治療調整。然而，人工智慧的有效性取決於檢驗的模型、代表性的資料集、透明的臨床決策支援、網路安全措施以及與工作流程的整合。在氣喘治療中，人工智慧最有價值的應用包括：基於循證醫學改進處方、減少可預防的病情加重、支持公平獲取專家級知識以及加強長期疾病管理，而不是取代臨床醫生的判斷。

關於氣喘藥物的關鍵區域性見解

亞太地區人口基數龐大，都市化進程加快，空氣污染嚴重，醫療基礎設施不斷完善，且對維持性吸入藥物和重症氣喘專科治療的需求日益成長，因此該地區在氣喘治療方面至關重要。該地區各地獲得肺功能檢查、吸入性糖皮質激素、生物製藥和呼吸專科醫生的機會各不相同，因此降低成本和落實指南是重中之重。北美地區有完善的氣喘指南，吸入性聯合治療廣泛應用，重症氣喘生物製藥治療途徑完善，數位健康工具普及率高，且保險公司高度重視實證醫學、藥物依從性和減少氣喘急性發作。拉丁美洲對氣喘管理的關注度也不斷提高，但診斷、維持性藥物、專科治療和病患教育方面的差異影響著治療效果，尤其是在服務不足的都市區社區。歐洲的優勢包括結構化的呼吸系統疾病診療路徑、強力的法律規範、積極參與環境健康政策以及擴大使用生物標記來指導重症氣喘的治療決策。在中東，由於粉塵暴露、氣候條件、城市發展、吸煙相關的呼吸系統風險以及獲得先進治療的機會不均等因素，氣喘管理面臨諸多挑戰，儘管對專科醫療保健的投入正在改善疾病管理能力。在非洲，亟需改善氣喘診斷、提供必要的吸入器、加強醫護人員訓練和病患教育，而治療效果往往受到診斷延遲、經濟障礙、肺功能檢測限制以及醫療保健系統內部其他優先事項的影響。

氣喘藥物的主要群體分析

在東協地區，快速的都市化、空氣品質問題、不同的保險報銷環境，以及在擴大吸入性皮質類固醇等治療藥物的可及性的同時，提高吸入技術和藥物依從性的需求，都在影響著氣喘藥物的需求。在海灣合作理事會（GCC）國家，呼吸系統護理正透過專科診所、對數位醫療的投資以及先進療法的廣泛應用而不斷進步，但暴露於環境粉塵、高溫和室內過敏原仍然是氣喘症狀的重要因素。歐盟透過協調藥品法規、藥物安全監測、衛生技術評估、環境政策和基於指南的醫療來支持氣喘治療，尤其注重透過適當的患者選擇來減少氣喘急性發作並最佳化重度氣喘生物製藥的使用。在金磚國家，氣喘治療現況各不相同。具體而言，這包括龐大的患者群體、不斷擴展的國家醫療保健系統、維持治療藥物可及性的差異、臨床研究參與度的提高，以及在臨床適用的情況下對價格合理的吸入器和生物製藥替代品日益成長的需求。七國集團（G7）國家通常為評估基於價值的氣喘治療提供了有利環境，這些國家擁有高度普及的先進診斷技術、維持治療方案、生物製藥、支持用藥依從性的數位化工具以及真實世界數據（REW）系統。北約成員國與北美和高所得歐洲國家的呼吸系統疾病治療系統高度重合，在這些國家，供應鏈韌性、藥物可近性、醫療安全和標準化臨床路徑都會影響公共衛生事件期間氣喘治療的連續性。

各國在氣喘治療的主要見解

美國擁有高度發展的氣喘治療體系，廣泛使用吸入性皮質類固醇聯合治療、生物製藥製劑治療重症氣喘、支持用藥依從性的數位化解決方案，以及以氣喘合格和治療結果為重點的保險公司主導的准入管理。在加拿大，重點在於基於指南的氣喘管理、與基層醫療的合作以及各省之間公平的藥物獲取，同時關注重症氣喘的轉診途徑和環境激勵措施。在墨西哥，優先事項仍然是改善診斷、提高維持性吸入器的可及性以及氣喘的氣喘越來越依賴專科中心和生物製藥的准入標準。在英國，循證氣喘管理透過國家臨床指南、品質改進計畫、對可預防的氣喘相關死亡的考慮、正確使用吸入器以及適當的抗發炎治療得到支持。在德國，一套完善的保險報銷流程，為系統化護理、專科醫生診療、呼吸系統診斷和先進療法提供了保障，並已被證明行之有效。在法國，重點在於協調的呼吸系統護理、藥物安全監測，以及利用生物標記和急性發作史評估重度氣喘。在俄羅斯，儘管對基本吸入療法的需求依然強勁，但不同地區獲得先進診斷和生物製藥的機會卻不盡相同。在義大利和西班牙，強大的呼吸系統專家網路和指南的採納正在穩步推進，人們越來越關注重度氣喘的表現型分析、藥物依從性以及減輕口服類固醇的負擔。在中國，面對都市區空氣品質的挑戰，氣喘的診斷和治療能力正在不斷提升，醫院呼吸系統照護水準得到改善，維持治療的普及率也更高。在印度，亟需價格合理的吸入藥物、改進的診斷方法、病患教育以及空氣污染相關呼吸道誘發因素的管理。在日本，先進的呼吸系統診斷技術、積極的臨床指南應用以及合格的重度氣喘患者獲得生物製藥的途徑都得到了保障。在澳大利亞，重點在於全國範圍內的氣喘控制、吸入器正確使用教育、過敏相關護理以及從初級到專科的數位化健康支援。在韓國，先進的醫療基礎設施、專業的呼吸系統醫療服務以及針對氣喘不佳和重度氣喘的精準治療方法的廣泛應用，都體現了這一點。

為氣喘治療領域的領導者提供的實用建議

產業領導者應優先考慮能夠改善可衡量的疾病控制、減少急性發作並提高實證治療公平性的氣喘治療策略。產品系列應涵蓋整個治療路徑，從價格適中的吸入型皮質類固醇療法和複方吸入劑，到針對重度氣喘表現型的標靶生物製藥。臨床和商業團隊應響應當前的指南趨勢，特別是「單純安寧療護」作用的減弱和抗發炎療法重要性的日益凸顯。對病人支持的投入應著重於吸入指引、用藥依從性、處方箋補充、避免誘發因素和協作決策，因為這些因素直接影響臨床實務中的療效。數位呼吸工具的開發人員應檢驗人工智慧和智慧吸入器解決方案在不同人群中的有效性，並將其結果整合到臨床醫生的工作流程中。在先進療法方面，領導者應加強生物標記檢測途徑、轉診網路、真實世界證據（REW）計畫以及能夠證明其可減少病情加重、急診就診、口服類固醇使用和生活品質下降的衛生經濟學數據。供應鏈規劃應考慮基本吸入器的供應、生物製藥的低溫運輸要求、監管差異以及中低收入國家所面臨的取得障礙。

氣喘藥物分析的調查方法

評估氣喘藥物的研究途徑應結合檢驗的二手研究、臨床指引審查、監管分析和結構化的專家解讀。可靠的資訊來源包括同行評審的呼吸醫學日誌、世界衛生組織、國家氣喘控制計畫、藥品監管機構、臨床試驗註冊庫、藥物安全監測資料庫、保險報銷指南和公共衛生資料集。調查方法應評估藥物分類、作用機制、患者表現型、處方趨勢、安全性考量、可近性以及減少病情惡化和控制疾病的證據。區域和國家層面的見解應根據醫療基礎設施指標、藥物可近性政策、診斷能力、環境風險因素和治療指南的採納檢驗。人工智慧和數位健康分析應包括模型檢驗、實際效用、資料隱私、互通性和臨床有效性。為維持客觀性，研究過程應排除無根據的說法，避免投機性的市場規模估算和預測，並依賴來自可靠的醫學、監管和公共衛生來源的多方面、檢驗的資訊來源。

結論

氣喘治療正朝著精準醫療、綜合疾病管理和以結果為導向的治療模式發展。關鍵變化包括吸入性糖皮質激素等療法的廣泛應用、擺脫單純安寧療護、擴大生物製藥在重度氣喘和控制不佳氣喘中的應用，以及引入數位化和人工智慧工具以提高藥物依從性、風險預測和臨床決策支援。區域差異依然顯著，尤其是在診斷、控制藥物、生物製藥、專科護理和病患教育的可近性方面。能夠將創新與基於指南的護理、可負擔性、真實世界療效和公平可及性相結合的行業相關人員，將更有能力支持臨床醫生並改善患者預後。氣喘治療的未來不僅取決於新藥的作用機制，還取決於能否在適當的時間為合適的患者提供適當的治療，同時減輕可預防的急性發作和長期疾病負擔。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章氣喘治療市場：依產品類型分類

  • 生物製劑
    • 抗IgE
    • 抗IL-5
  • 吸入器
    • 乾粉吸入器
    • 定量噴霧吸入器
    • 緩霧吸入器
  • 噴霧器
    • 噴射式霧化器
    • 篩孔式噴霧器
    • 超音波霧化器
  • 口服藥物
    • 白三烯調節劑
    • 口服類固醇
    • 茶鹼

第8章：氣喘治療市場：依氣喘類型分類

  • 過敏性氣喘
  • 非過敏性氣喘
  • 嗜酸性粒細胞氣喘
  • 職業性氣喘

第9章：氣喘治療市場：依藥物類別分類

  • BETA-激動劑
  • 聯合治療
  • 吸入性皮質類固醇
  • 白三烯調節劑
  • 單株抗體

第10章：氣喘治療市場：依給藥途徑分類

  • 吸入
  • 口服
    • 藥片
    • 膠囊
    • 糖漿
  • 注射藥物
    • 靜脈
    • 皮下
    • 肌肉內部

第11章氣喘治療市場：依治療類型分類

  • 維持治療
  • 急診醫學

第12章：氣喘治療市場：依患者類型分類

  • 兒童
  • 成人
  • 老年人

第13章：氣喘治療市場：依最終用戶分類

  • 醫院
  • 專科診所
  • 居家照護環境
  • 門診部

第14章：氣喘治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第15章：氣喘治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章：氣喘治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章氣喘治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Almirall SA
  • Amgen Inc.
  • Areteia Therapeutics
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • Cipla Limited
  • F. Hoffmann-La Roche Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • GSK plc
  • Hikma Pharmaceuticals PLC
  • Innoviva Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co. Inc.
  • Mundipharma International Limited
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma Inc.
  • Vectura Group plc
  • Verona Pharma plc
  • Viatris Inc.
Product Code: MRR-AB49FC1AB810

The Asthma Therapeutics Market is projected to grow by USD 42.07 billion at a CAGR of 5.84% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 28.26 billion
Estimated Year [2026] USD 29.81 billion
Forecast Year [2032] USD 42.07 billion
CAGR (%) 5.84%

Asthma therapeutics are entering a more precision-driven era as clinicians, payers, and public health systems respond to the continuing burden of a chronic inflammatory airway disease that affects children and adults worldwide. Verified global health evidence identifies asthma as a major noncommunicable respiratory condition associated with wheeze, breathlessness, chest tightness, cough, emergency visits, lost productivity, and avoidable mortality when symptoms are uncontrolled. The therapeutic landscape spans inhaled corticosteroids, long-acting bronchodilators, leukotriene pathway modifiers, short-acting relievers, combination inhalers, oral corticosteroids for exacerbations, and targeted biologics for severe asthma phenotypes. Current clinical guidance increasingly emphasizes anti-inflammatory reliever strategies, adherence optimization, correct inhaler technique, personalized stepwise treatment, and risk reduction for exacerbations rather than symptom relief alone. SEO-relevant industry themes shaping asthma therapeutics include severe asthma biologics, eosinophilic asthma treatment, allergic asthma management, inhaled corticosteroid adherence, smart inhalers, digital respiratory care, pediatric asthma therapy, and value-based respiratory disease management.

Transformative Shifts in the Asthma Therapeutics Landscape

The asthma therapeutics landscape is being reshaped by clinical, regulatory, technological, and environmental shifts. A central transformation is the movement from one-size-fits-all bronchodilation toward phenotype- and biomarker-informed care, including the use of blood eosinophils, immunoglobulin E status, fractional exhaled nitric oxide, exacerbation history, comorbidities, and treatment response to guide therapy selection in severe asthma. Guidelines increasingly discourage reliance on short-acting beta agonist-only treatment because overuse is associated with higher exacerbation risk, while inhaled corticosteroid-containing regimens remain foundational for reducing airway inflammation. Another major shift is the expansion of biologic therapies targeting type 2 inflammation pathways, supporting treatment of patients with severe uncontrolled asthma who remain symptomatic despite optimized inhaled therapy. At the same time, digital inhalers, connected nebulization systems, remote monitoring, and electronic adherence tools are changing how clinicians identify poor technique, nonadherence, and worsening control. Environmental and occupational triggers, air pollution, climate-related allergen exposure, viral respiratory infections, tobacco smoke exposure, and indoor air quality continue to influence disease control, making asthma therapeutics increasingly linked to prevention, diagnostics, and population health interventions.

Cumulative Impact of Artificial Intelligence on Asthma Therapeutics

Artificial intelligence is creating cumulative impact across asthma therapeutics by improving diagnosis support, risk stratification, inhaler adherence monitoring, clinical trial design, and real-world evidence generation. AI-enabled algorithms can analyze electronic health records, pharmacy refill patterns, spirometry results, symptom diaries, claims data, wearable signals, and environmental exposure information to identify patients at elevated risk of exacerbations or poor control. In clinical development, machine learning supports biomarker discovery, patient enrichment for severe asthma trials, protocol optimization, and analysis of heterogeneous treatment response across phenotypes such as eosinophilic, allergic, non-type 2, exercise-induced, and pediatric asthma. In care delivery, AI-powered digital respiratory platforms can help detect reliever overuse, missed controller doses, abnormal peak-flow trends, and seasonal trigger patterns, enabling earlier therapeutic adjustment. However, the impact of AI depends on validated models, representative datasets, transparent clinical decision support, cybersecurity safeguards, and workflow integration. For asthma therapeutics, the highest-value AI applications are those that improve evidence-based prescribing, reduce preventable exacerbations, support equitable access to specialist-level insights, and strengthen long-term disease control without replacing clinician judgment.

Key Regional Insights for Asthma Therapeutics

Asia-Pacific is a critical asthma therapeutics region due to its large population base, urbanization, air pollution exposure, expanding healthcare infrastructure, and rising demand for both controller inhalers and severe asthma specialty care. Countries across the region face varied access to spirometry, inhaled corticosteroids, biologics, and respiratory specialists, making affordability and guideline implementation central priorities. North America is characterized by established asthma guidelines, broad availability of inhaled combination therapy, biologic treatment pathways for severe asthma, high adoption of digital health tools, and strong emphasis on payer evidence, adherence, and exacerbation reduction. Latin America shows growing attention to asthma control, but therapeutic outcomes are influenced by unequal access to diagnostics, controller medicines, specialist care, and patient education, particularly across underserved urban and rural communities. Europe benefits from structured respiratory care pathways, strong regulatory oversight, environmental health policy engagement, and increasing use of biomarkers to guide severe asthma treatment decisions. The Middle East faces asthma management challenges linked to dust exposure, climate conditions, urban development, smoking-related respiratory risk, and variability in access to advanced therapies, while investment in specialized care is improving disease management capacity. Africa carries a substantial need for improved asthma diagnosis, essential inhaled medicines, healthcare worker training, and patient education, with outcomes often affected by underdiagnosis, affordability barriers, limited pulmonary function testing, and competing health system priorities.

Key Group Insights for Asthma Therapeutics

Within ASEAN, asthma therapeutics demand is shaped by rapid urbanization, air quality concerns, diverse reimbursement environments, and the need to expand access to inhaled corticosteroid-containing treatment while improving inhaler technique and adherence. GCC countries are advancing respiratory care through specialist clinics, digital health investment, and greater availability of advanced therapies, although environmental dust, heat, and indoor allergen exposure remain important contributors to asthma symptoms. The European Union supports asthma therapeutics through harmonized medicine regulation, pharmacovigilance, health technology assessment, environmental policy, and guideline-based care, with strong emphasis on reducing exacerbations and optimizing severe asthma biologic use through appropriate patient selection. BRICS economies reflect a mixed asthma therapeutic environment: large patient populations, expanding domestic healthcare capacity, uneven access to controller medicines, increasing clinical research participation, and growing demand for affordable inhalers and biologic alternatives where clinically appropriate. G7 countries generally demonstrate higher availability of advanced diagnostics, controller therapies, biologics, digital adherence tools, and real-world evidence systems, making them important settings for evaluating value-based asthma care. NATO member countries overlap significantly with high-income respiratory care systems in North America and Europe, where supply chain resilience, medicine access, health security, and standardized clinical pathways influence continuity of asthma therapeutics during public health disruptions.

Key Country Insights for Asthma Therapeutics

The United States has a highly developed asthma therapeutics ecosystem with broad use of inhaled corticosteroid combinations, biologics for severe asthma, digital adherence solutions, and payer-driven utilization management focused on clinical eligibility and outcomes. Canada emphasizes guideline-based asthma control, primary care integration, and equitable medicine access across provinces, with attention to severe asthma referral pathways and environmental triggers. Mexico continues to prioritize improved diagnosis, access to controller inhalers, and asthma education, especially where out-of-pocket costs and variable specialist availability affect continuity of care. Brazil combines a large respiratory disease burden with public health initiatives and demand for affordable inhaled medicines, while severe asthma care is increasingly shaped by specialist centers and biologic access criteria. The United Kingdom supports evidence-based asthma management through national clinical guidance, quality improvement programs, and attention to preventable asthma deaths, inhaler technique, and appropriate anti-inflammatory therapy. Germany benefits from structured care, specialist access, pulmonary diagnostics, and robust reimbursement review processes for advanced therapies. France emphasizes coordinated respiratory care, pharmacovigilance, and severe asthma assessment using biomarkers and exacerbation history. Russia faces regional variability in access to advanced diagnostics and biologics while maintaining demand for essential inhaled therapies. Italy and Spain have strong respiratory specialist networks, guideline adoption, and growing focus on severe asthma phenotyping, adherence, and reducing oral corticosteroid burden. China is expanding asthma diagnosis and treatment capacity amid urban air quality challenges, increasing hospital-based respiratory care, and broader adoption of controller therapy. India shows substantial need for affordable inhaled medicines, improved diagnosis, patient education, and management of pollution-related respiratory triggers. Japan has advanced respiratory diagnostics, strong clinical guideline use, and access to biologics for eligible severe asthma patients. Australia emphasizes national asthma strategies, inhaler technique education, allergy-linked care, and digital health support across primary and specialist settings. South Korea combines advanced healthcare infrastructure, specialist respiratory services, and growing use of precision treatment approaches for uncontrolled and severe asthma.

Actionable Recommendations for Asthma Therapeutics Leaders

Industry leaders should prioritize asthma therapeutics strategies that improve measurable disease control, reduce exacerbations, and expand equitable access to evidence-based care. Product portfolios should support the full treatment continuum, from affordable inhaled corticosteroid-containing therapy and combination inhalers to targeted biologics for severe asthma phenotypes. Clinical and commercial teams should align with current guideline trends, especially the reduced role of reliever-only treatment and the importance of anti-inflammatory therapy. Investment in patient support should focus on inhaler technique, adherence, refill continuity, trigger avoidance, and shared decision-making, as these factors directly influence real-world outcomes. Developers of digital respiratory tools should validate AI and connected inhaler solutions in diverse populations and integrate outputs into clinician workflows. For advanced therapies, leaders should strengthen biomarker testing pathways, referral networks, real-world evidence programs, and health economic dossiers that demonstrate reductions in exacerbations, emergency visits, oral corticosteroid exposure, and quality-of-life impairment. Supply chain planning should account for essential inhaler availability, cold-chain requirements for biologics, regulatory variability, and access barriers in low- and middle-income settings.

Research Methodology for Asthma Therapeutics Analysis

The research approach for evaluating asthma therapeutics should combine verified secondary research, clinical guideline review, regulatory analysis, and structured expert interpretation. Reliable sources include peer-reviewed respiratory medicine journals, global health agencies, national asthma programs, drug regulatory authorities, clinical trial registries, pharmacovigilance databases, reimbursement guidance, and public health datasets. The methodology should assess therapeutic classes, mechanisms of action, patient phenotypes, prescribing trends, safety considerations, access conditions, and evidence on exacerbation reduction and disease control. Regional and country insights should be validated against healthcare infrastructure indicators, medicine access policies, diagnostic capacity, environmental risk factors, and treatment guideline adoption. Artificial intelligence and digital health analysis should include model validation, real-world usability, data privacy, interoperability, and clinical relevance. To maintain objectivity, the research process should exclude unsupported claims, avoid speculative market sizing or forecasting, and rely on triangulated evidence from credible medical, regulatory, and public health sources.

Conclusion

Asthma therapeutics are moving toward precision care, integrated disease management, and outcome-focused treatment models. The most important shifts include greater use of inhaled corticosteroid-containing regimens, reduced dependence on reliever-only approaches, expansion of biologics for severe uncontrolled asthma, and adoption of digital and AI-enabled tools to improve adherence, risk prediction, and clinical decision support. Regional differences remain substantial, particularly in access to diagnostics, controller medicines, biologics, specialist care, and patient education. Industry participants that align innovation with guideline-based care, affordability, real-world effectiveness, and equitable access will be better positioned to support clinicians and improve patient outcomes. The future of asthma therapeutics will be defined not only by new drug mechanisms but also by the ability to deliver the right therapy to the right patient at the right time, while reducing preventable exacerbations and long-term disease burden.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Asthma Therapeutics Market, by Product Type

  • 7.1. Introduction
  • 7.2. Biologics
    • 7.2.1. Anti-Ige
    • 7.2.2. Anti-Il5
  • 7.3. Inhalers
    • 7.3.1. Dry Powder Inhalers
    • 7.3.2. Metered Dose Inhalers
    • 7.3.3. Soft Mist Inhalers
  • 7.4. Nebulizers
    • 7.4.1. Jet Nebulizers
    • 7.4.2. Mesh Nebulizers
    • 7.4.3. Ultrasonic Nebulizers
  • 7.5. Oral Drugs
    • 7.5.1. Leukotriene Modifiers
    • 7.5.2. Oral Corticosteroids
    • 7.5.3. Theophylline

8. Asthma Therapeutics Market, by Asthma Type

  • 8.1. Introduction
  • 8.2. Allergic Asthma
  • 8.3. Non-allergic Asthma
  • 8.4. Eosinophilic Asthma
  • 8.5. Occupational Asthma

9. Asthma Therapeutics Market, by Drug Class

  • 9.1. Introduction
  • 9.2. Beta Agonists
  • 9.3. Combination Therapies
  • 9.4. Inhaled Corticosteroids
  • 9.5. Leukotriene Modifiers
  • 9.6. Monoclonal Antibodies

10. Asthma Therapeutics Market, by Route Of Administration

  • 10.1. Introduction
  • 10.2. Inhalation
  • 10.3. Oral
    • 10.3.1. Tablets
    • 10.3.2. Capsules
    • 10.3.3. Syrups
  • 10.4. Injectable
    • 10.4.1. Intravenous
    • 10.4.2. Subcutaneous
    • 10.4.3. Intramuscular

11. Asthma Therapeutics Market, by Therapy Type

  • 11.1. Introduction
  • 11.2. Maintenance Therapy
  • 11.3. Rescue Therapy

12. Asthma Therapeutics Market, by Patient Type

  • 12.1. Introduction
  • 12.2. Pediatric
  • 12.3. Adult
  • 12.4. Geriatric

13. Asthma Therapeutics Market, by End User

  • 13.1. Introduction
  • 13.2. Hospitals
  • 13.3. Specialty Clinics
  • 13.4. Homecare Settings
  • 13.5. Ambulatory Care Centers

14. Asthma Therapeutics Market, by Distribution Channel

  • 14.1. Introduction
  • 14.2. Hospital Pharmacy
  • 14.3. Online Pharmacy
  • 14.4. Retail Pharmacy

15. Asthma Therapeutics Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Asthma Therapeutics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Asthma Therapeutics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2025
  • 18.2. FPNV Positioning Matrix, 2025
  • 18.3. Market Concentration Analysis, 2025
    • 18.3.1. Concentration Ratio (CR)
    • 18.3.2. Herfindahl Hirschman Index (HHI)
  • 18.4. Recent Developments & Impact Analysis, 2025
  • 18.5. Product Portfolio Analysis, 2025
  • 18.6. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. Abbott Laboratories
  • 19.2. AbbVie Inc.
  • 19.3. Almirall S.A.
  • 19.4. Amgen Inc.
  • 19.5. Areteia Therapeutics
  • 19.6. AstraZeneca PLC
  • 19.7. Aurobindo Pharma Limited
  • 19.8. Boehringer Ingelheim International GmbH
  • 19.9. Chiesi Farmaceutici S.p.A.
  • 19.10. Cipla Limited
  • 19.11. F. Hoffmann-La Roche Ltd.
  • 19.12. Glenmark Pharmaceuticals Ltd.
  • 19.13. GSK plc
  • 19.14. Hikma Pharmaceuticals PLC
  • 19.15. Innoviva Inc.
  • 19.16. Johnson & Johnson Services, Inc.
  • 19.17. Lupin Limited
  • 19.18. Merck & Co. Inc.
  • 19.19. Mundipharma International Limited
  • 19.20. Novartis AG
  • 19.21. Orion Corporation
  • 19.22. Pfizer Inc.
  • 19.23. Regeneron Pharmaceuticals Inc.
  • 19.24. Sanofi S.A.
  • 19.25. Sun Pharmaceutical Industries Ltd.
  • 19.26. Teva Pharmaceutical Industries Ltd.
  • 19.27. Theravance Biopharma Inc.
  • 19.28. Vectura Group plc
  • 19.29. Verona Pharma plc
  • 19.30. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ASTHMA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ASTHMA THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ASTHMA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ASTHMA THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ASTHMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 29. GLOBAL ASTHMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ASTHMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-IGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-IGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-IGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-IL5 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-IL5 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-IL5 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INHALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INHALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INHALERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRY POWDER INHALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRY POWDER INHALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRY POWDER INHALERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL METERED DOSE INHALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL METERED DOSE INHALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL METERED DOSE INHALERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SOFT MIST INHALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SOFT MIST INHALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SOFT MIST INHALERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEBULIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEBULIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEBULIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL JET NEBULIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL JET NEBULIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL JET NEBULIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MESH NEBULIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MESH NEBULIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MESH NEBULIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ULTRASONIC NEBULIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ULTRASONIC NEBULIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ULTRASONIC NEBULIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LEUKOTRIENE MODIFIERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LEUKOTRIENE MODIFIERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LEUKOTRIENE MODIFIERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL THEOPHYLLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL THEOPHYLLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL THEOPHYLLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-ALLERGIC ASTHMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NON-ALLERGIC ASTHMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-ALLERGIC ASTHMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL EOSINOPHILIC ASTHMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL EOSINOPHILIC ASTHMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EOSINOPHILIC ASTHMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OCCUPATIONAL ASTHMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OCCUPATIONAL ASTHMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OCCUPATIONAL ASTHMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BETA AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BETA AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BETA AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INHALED CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INHALED CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INHALED CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LEUKOTRIENE MODIFIERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LEUKOTRIENE MODIFIERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LEUKOTRIENE MODIFIERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SYRUPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SYRUPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SYRUPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RESCUE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RESCUE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RESCUE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 254. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 256. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 257. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 258. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 259. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 263. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 264. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. GCC ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 299. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 301. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 302. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 303. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 304. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 306. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 308. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 309. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. G7 ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 313. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 314. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 316. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 317. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 318. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 319. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 321. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 322. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 323. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 324. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. NATO ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 328. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2018-2032 (USD MILLION)
  • TABLE 336. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 338. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 339. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 340. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 344. CANADA ASTHMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 345. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 347. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 348. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 349. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 350. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 352. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 353. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 354. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 355. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 356. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 357. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 358. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 359. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 360. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 361. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 362. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2032 (USD MILLION)
  • TABLE 363. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 364. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL DRUGS, 2018-2032 (USD MILLION)
  • TABLE 365. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY ASTHMA TYPE, 2018-2032 (USD MILLION)
  • TABLE 366. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 367. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 368. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 369. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 370. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 371. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 372. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

TA